视神经脊髓炎谱系疾病免疫靶向药物治疗研究进展  

Progress of Specifc Targeting Immunotherapy in Neuromyelitis Optica Spectrum Disorder

作　　者：蔡同甲 王蓓 邬剑军 CAI Tong-jia;WANG Bei;WU Jian-jun(Department of Neurology, Jing＇an District Centre Hospital of Shanghai, Fudan University, Shanghai 200040, China;Department of Neurology, Huashan Hospital, Fudan University, Shanghai 200040, China)

机构地区：[1]静安区中心医院神经内科,上海200040 [2]复旦大学附属华山医院神经内科,上海200040

出　　处：《中国临床神经科学》2018年第3期314-319,355,共7页Chinese Journal of Clinical Neurosciences

基　　金：第三批"静安区卫生系统十百千"人才专业技术骨干资助项目(编号:JWRC2014G0)

摘　　要：视神经脊髓炎谱系疾病是一种抗体介导的获得性自身免疫性疾病。近年,多种免疫靶向药物被批准用于治疗视神经脊髓炎谱系疾病。因为疗效确切,靶向性特异性免疫治疗极大的改变了视神经脊髓炎谱系疾病患者的预后。本文将从靶点、疗效、不良反应等方面综述靶向性特异性免疫治疗进展。Neuromyelitis optica spectrum disorder（NMOSD） is an antibody mediated,acquired autoimmune disorder.Some targeted agents have been approved to treat NMOSD in recent years.Due to specificity and uniformity,symptoms significantly were improved in some NMOSD patients after the targeting immunotherapy.The targets,clinical results and adverse events of specifc targeting immunotherapy in neuromyelitis optica spectrum disorder were reviewed.

关 键 词：视神经脊髓炎谱系疾病 靶向性特异性免疫治疗 单克隆抗体 硼替佐米 

分 类 号：R744.5[医药卫生—神经病学与精神病学]